StockNews.AI
ABBV
StockNews.AI
193 days

U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options

1. ABBV's EMBLAVEOTM received FDA approval as the first monobactam/β-lactamase inhibitor. 2. This approval addresses critical antimicrobial resistance issues with Gram-negative bacteria.

2m saved
Insight
Article

FAQ

Why Bullish?

The approval enhances ABBV's product portfolio and market position in antibiotics, similar to past successes with other FDA-approved drugs.

How important is it?

EMBLAVEOTM's unique positioning in addressing AMR aligns with global health priorities, potentially influencing investor sentiments towards ABBV's growth strategy.

Why Long Term?

The introduction of EMBLAVEOTM is expected to generate sustained revenue streams, indicating substantial long-term growth potential.

Related Companies

ABBVAVBPFEMRK
EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies Antimicrobial resistance (AMR) could lead to over 39 million deaths worldwide by 2050, and new treatments are urgently needed1 NORTH CHICAGO, Ill. , Feb. 7, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic.

Related News